Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014411 | 0.90 | SOS1 (0.39) | DRD3AVPR1ASOS1DRD2HTR1A | |
| SCHEMBL2015384 | 0.83 | SOS1 (0.42) | DRD3AVPR1ASOS1DRD2HTR1A | |
| SCHEMBL2017960 | 0.82 | ADRA1B (0.45) | DRD3SOS1HTR1ACYP2C8CYP2D6 | |
| SCHEMBL2019939 | 0.82 | ADRA1B (0.45) | DRD3SOS1HTR1ACYP2C8CYP2D6 | |
| SCHEMBL2015836 | 0.74 | HTR2C (0.52) | — | |
| SCHEMBL2019235 | 0.74 | HTR2C (0.52) | — | |
| SCHEMBL2016301 | 0.74 | DRD2 (0.47) | DRD2HTR1ACYP2D6 | |
| SCHEMBL2015572 | 0.73 | DRD2 (0.41) | DRD3SOS1DRD2HTR1ACYP2D6 | |
| SCHEMBL2014035 | 0.72 | DRD2 (0.47) | DRD3DRD2HTR1ACYP2D6 | |
| SCHEMBL2020598 | 0.71 | DRD2 (0.47) | DRD2HTR1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | claimed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | claimed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | claimed |
| EP-3150607-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2560973-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133182-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | DRD3 91/4885AVPR1A 345/4885SOS1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.